


Our Sustainability Impact

Building a healthy future for
people, society and the planet

May 2025





Contents

The second edition of our Sustainability Impact Publication spotlights how AstraZeneca is working to improve the health of people, society and the planet.

Leading in Sustainability

- 3** A letter from Pam Cheng, EVP, Global Operations, IT and Chief Sustainability Officer
- 4** Our approach to Sustainability
- 7** Our positive impact

Climate and nature action

- 9** Addressing the intersection of human and planetary health
- 11** Decarbonising respiratory care – from lab bench to patient bedside
- 12** Healthier patient, greener patient
- 14** A digital-first solution for patient information
- 15** Powering medicines manufacturing with renewable energy
- 18** An award-winning Sustainability culture
- 19** Mitigating the risks of climate change to drive business resilience
- 20** Expanding renewable power for healthcare in China
- 20** Contributing to the circular economy
- 21** Protecting and restoring nature

Health equity

- 24** Helping more people live their healthiest life
- 25** Ensuring our science represents those most impacted by disease
- 27** Improving lung health equity
- 29** Addressing heart and kidney health in vulnerable communities
- 30** Empowering global young health leaders

Health equity cont.

- 32** Supporting community recovery and resilience
- 33** Improving access to healthcare

Health systems resilience

- 35** Building health systems for today and tomorrow
- 36** Improving patient outcomes and reducing disease progression
- 37** Strengthening health systems through public-private partnerships
- 38** Educating the next generation to deliver sustainable healthcare

How we do business

- 40** Our Values
- 41** Our people
- 42** Our governance and ethics

The road to 2030



A letter from Pam Cheng

Dear partners,

We are in an unprecedented era of science and innovation, with the potential to deliver medical breakthroughs and transform healthcare for billions of people worldwide. Fuelled by cutting-edge technologies, artificial intelligence and digital tools, we're witnessing firsthand the extraordinary capacity of what science can do to improve the health of people, society and our planet.

Yet, the challenges are significant. Ageing populations, the rising burden of chronic diseases, environmental impacts on health and fiscal pressures make it increasingly hard for health systems to cope and keep pace with the latest scientific advancements. This makes collaboration through public-private partnerships so vital – we must work across and beyond our sector to ensure that medical innovations can reach more people. We know that detecting and treating disease early improves health outcomes, relieves pressure on health systems and budgets, and reduces the environmental footprint of healthcare – that's a 'triple win'.

At AstraZeneca, we embrace the role we play in transforming healthcare. We are investing in the future of medicine, but our commitment doesn't end here. We're also working hard to make a positive impact – by closing healthcare gaps to improve health equity, strengthening health systems to be more resilient, and supporting the health of our planet by reducing our environmental footprint and investing in nature.

This is more than just the right thing to do. It's fundamental to the sustainability of our business. Operating sustainably makes good business sense, driving efficiencies and building long-term resilience. Since 2015, AstraZeneca has reduced emissions from our research and development (R&D) and manufacturing sites, as well as our fleet, by 78% while doubling our business – a clear testament to the fact that sustainable growth is achievable.

Within this publication, I hope you'll be inspired by both how we're making a sustainable impact and how we're leading a sustainable business that is underpinned by our governance and ethics, our people and our Values. And, I encourage you to consider how we can enhance our impact together.

I am proud of what we have accomplished, but I also know there is more we must do. As we continue to navigate the world around us, I invite you to join us in following the science and unlocking the power of innovation to build a more sustainable future.

Sincerely,

Pam Cheng
EVP, Global Operations & IT and
Chief Sustainability Officer, AstraZeneca



Our approach to Sustainability

At AstraZeneca, we're committed to improving the health of people, society and the planet.

Recognising the strong connection between business growth and resilience, and the need to address the major health challenges of our time, our approach to Sustainability focuses on how we make a sustainable impact and how we do business:

- **How we make a sustainable impact**
Through the power of science and innovation, we are taking action on climate and nature, health equity and health systems resilience.
- **How we do business**
We are guided by our Values and invest in our people to create long-term value, resilience and trust by operating responsibly, ethically and with robust governance.






Our Sustainability impact

We're playing our part to address the complex, interconnected challenges facing healthcare and prioritising areas where collaboration across and beyond the health sector can deliver long-term positive impact.

We're taking action on:

- **Climate and nature**
Reducing our impact on the planet and helping protect and restore our natural environment.
- **Health equity**
Closing healthcare gaps to give people everywhere the chance to be as healthy as possible.
- **Health systems resilience**
Contributing to stronger health systems that can meet the health needs of today and tomorrow.





How we do business

Sustainability is fundamental to the long-term success of our company. It is also integral to how we engage with patients, caregivers, healthcare professionals (HCPs), suppliers, partners and communities.

We're focused on:

- **Our Values**
They guide our decision-making, define our behaviours and help foster a strong culture at AstraZeneca.
- **Our people**
We create great employee experiences that ignite innovation, unite diverse talent and unlock capacity.
- **Our governance and ethics**
We ensure robust governance through our values-based culture, grounded in ethics and integrity, and supported by clear expectations outlined in policies and standards with independent oversight from our Board.



Our positive impact



90.4 million

People reached through access to healthcare programmes
(Cumulative)



\$126.7 million

Total community investment across 65 countries*



156,810

Healthcare workers trained since 2010



40+ million

Trees planted across six continents since 2020



19.5+ million

Young people directly reached through our Young Health Programme since 2010



12.9 million

People with elevated blood pressure linked to care through Healthy Heart Africa since 2014



20

Countries with supplier diversity programmes outside the US



77.5%

Reduction in Scope 1 and 2 greenhouse gas (GHG) emissions vs 2015



23%

Reduction in our water use vs 2015



63%

Of our car fleet are battery electric vehicles

Data as of December 2024 (Source: Sustainability Data Annex 2024)
* Not including Patient Assistance Programmes



Taking action on climate and nature

We aim to reduce our impact on the planet
and help restore our natural world



Addressing the intersection of human and planetary health

We aim to halve our entire value chain footprint by 2030* on the way to a 90% reduction by 2045 to achieve science-based net zero. In addition, we aim to plant and monitor 200 million trees across six continents through AZ Forest and are prioritising the sustainable sourcing of priority agricultural, mining, forestry and marine-derived materials used in products and research activities.**

Human health is intrinsically linked to the health of our planet – through the air we breathe, the water we drink and the environments we live in. World Health Organization¹ data shows that an estimated 24% of all global deaths are linked to environmental conditions.

The natural world plays a key role in mitigating the impacts of climate change and supporting resilient ecosystems and biodiversity, all of which are linked to human health. Contributing to both climate and nature action is critical for life on Earth.

We are decarbonising our business and value chain because we recognise that while the health sector aims to keep people healthy, it also has a significant environmental impact, accounting for around 5% of GHG emissions.² We are also focused on nature action because we know that the R&D, manufacture and delivery of life-changing medicines to patients also uses resources from and has impact on the natural world. We are playing our part to reduce our dependencies and impact on the environment, together with expert partners.

Through our [Ambition Zero Carbon](#) strategy, we are investing more than \$1 billion to support our transition to net zero, as well as \$400 million in our [AZ Forest](#) programme, and leading other environmental protection initiatives.

*2030 targets based on assumptions at time of target setting
**In alignment with the SBTi Corporate Net-Zero Standard



We're taking action across:

- **Our operations**

We are working to avoid and eliminate environmental impact throughout the design and development of our medicines. We are eliminating emissions across our R&D and manufacturing operations and fleet, ensuring more efficient use of water and materials and reducing waste, while growing our business.

- **Our value chain**

We are working collaboratively with our suppliers and partners to encourage them to pursue science-based targets. To date, more than 1,000 of our suppliers have committed to having science-based targets and around one in 10 of all companies that have signed up to the Science Based Targets initiative are AstraZeneca partners.

We are also supporting our suppliers to transition to more sustainable approaches by sharing innovative decarbonisation solutions, including through Energize.

- **Our sector and beyond**

We are driving change to advance towards more sustainable, net-zero healthcare, including through flagship public-private partnerships such as the Sustainable Markets Initiative (SMI) Health Systems Task Force, chaired by AstraZeneca CEO Pascal Soriot. We are also collaborating with stakeholders to protect and restore ecosystems through a focus on water stewardship and preserving biodiversity.





Decarbonising respiratory care – from lab bench to patient bedside

Poor air quality is contributing to the rise of chronic respiratory diseases³ and can result in exacerbations and hospitalisations⁴ for patients with respiratory illnesses that are not well-controlled.

The climate crisis, pollution and other environmental factors contribute to the burden of chronic respiratory diseases, with air pollution killing an estimated 7 million people every year.⁵

At the same time, caring for millions of people with respiratory conditions carries an environmental impact. For example, COPD is the leading cause of hospitalisations in many countries and this has a significant environmental footprint. AstraZeneca is taking action to address the interconnection of the climate's impact on health, as well as the impact of healthcare on the climate.

Through our Ambition Zero Carbon strategy, we are pioneering sustainable science and medicine to support population and planetary health, with respiratory sustainability representing a key area of focus.

Optimising the care of patients with respiratory conditions by implementing guideline-directed medical therapy is critical to improve health outcomes and reduce the environmental footprint of care. To play our part in decarbonising respiratory care, we are transitioning our inhaled respiratory medicines delivered by pressurised Metered Dose Inhalers (pMDIs) to an innovative next-generation propellant with near-zero Global Warming Potential, to ensure clinical decisions can guide getting the right medicine to the right patients. It is critical that respiratory clinicians and their patients don't feel that they have to choose between the most appropriate treatment and the environment.

In May 2025, in a world-first, we received approval for one of our inhaled respiratory medicines using the next-generation propellant in the UK. We have submitted regulatory filings in the EU and China as well and aim to transition our wider pMDI portfolio to the near-zero Global Warming Potential propellant by 2030 as part of our Ambition Zero Carbon strategy.⁶

Another innovation in respiratory sustainability is demonstrated by our site in Dunkirk, France, which is a world-class facility for the manufacture of inhaled devices. The Dunkirk team is innovating production-line processes to eliminate and capture F-gas emissions from the manufacturing of inhaled medications. Through a process change involving purging empty canisters in a vacuum instead of using a propellant, the site has significantly reduced emissions. Additionally, in 2024, we scaled up an initiative to capture F-gases emitted during the production process, using cryogenic technology to liquefy gases to enable their safe storage and removal for either incineration or recycling.

These are some concrete ways in which we are embedding innovation into our science and technology to contribute to a low-carbon, circular economy which supports the health of people, society and the planet.





Healthier patient, greener patient

From cardiovascular diseases and diabetes to cancers and chronic respiratory diseases, non-communicable diseases (NCDs) affect people across all age groups, regions and countries and the burden of these diseases is rising.

Tackling the growing burden of NCDs has the potential to positively impact health outcomes, health systems, economies and the environment. A McKinsey report found that one-third of economic growth⁷ in advanced economies in the past century can be attributed to improvements in health. In developing countries, Brookings found that for every \$1 invested in health, there is a possible economic return of between \$2 to \$4.⁸

To realise this enormous opportunity, health systems must shift from reactive 'sick care' to 'health care', with greater focus on prevention, early diagnosis and the delivery of evidence-based, guideline-directed treatment. At AstraZeneca, we are taking a systems-approach with our partners to transform the delivery of healthcare.

43 million

people who die
annually from NCDs⁹

80%

of deaths from NCDs that
could be prevented or
delayed into old age^{9,10}





Prioritising early detection for chronic kidney disease (CKD)

CKD remains a major public health challenge, with 2.5 million patients currently on dialysis – a number projected to rise to 5.4 million by 2030. This surge puts an unsustainable burden on healthcare systems and the environment, as dialysis is highly resource-intensive,¹¹ consuming over 169 billion litres of water and producing more than one billion kilograms of medical waste annually.

Our ambition is to support the screening of 140 million people at risk for CKD by partnering with key healthcare stakeholders and policymakers. We aim to reduce kidney failure cases by 20% by the end of 2025 and help transform kidney health.

Evidence generation to quantify the emissions of suboptimal asthma care


Alongside transitioning our inhaled respiratory medicines to a next-generation propellant with near-zero Global Warming Potential, we are working to address the impact that asthma and chronic obstructive pulmonary disease (COPD) exacerbations and hospitalisations have on both patients and the planet by generating evidence to quantify the GHG emissions of suboptimal care.

This includes a study that shows patients with poorly-controlled COPD saw on average a 50% increase in the GHG emissions of their care for each year of follow-up compared to those with well-controlled disease.

CARESA: using data to transform care

AstraZeneca medical and sustainability teams developed the CARE pathway Environmental Sustainability Assessment (**CARESA**) modelling tool to support our ambition to accelerate the transition to net zero healthcare and transform how healthcare is delivered.

CARESA allows users to model the environmental impact of a patient care pathway, compare different care pathways and model the effects of different interventions. It is suitable for application in any disease area. CARESA launched for testing in early 2025 and AstraZeneca has made it open access for other healthcare companies and systems to beta test – we deem it important to collect as much data as possible on how to decarbonise patient care pathways.



A digital-first solution for patient information

To ensure patients and HCPs have the information they need to take or prescribe medicines safely and effectively, all medicine packs are required to include a patient information leaflet (PIL). Electronic Product Information (ePI) – an electronic version of this leaflet – can make product information available to patients, carers and HCPs digitally. By scanning a QR code on the medicine pack, access to the latest product information is accelerated, avoiding the need for a paper leaflet.

Digital access to medicine product information has the potential to improve patient safety by enabling more frequent and timely updates. ePI also supports greater accessibility through adaptable font sizes, multiple formats, search functionality, and, in future, potential integration of video and audio content. Transitioning to digital medicine information may also accelerate the availability of new medicines by reducing reliance on printed materials and enabling quicker regulatory implementation. In Singapore, the transition to ePI has enabled medicines to launch up to three months earlier than if a printed leaflet had been required.

In addition to improving patient access, ePI can offer significant environmental benefits. Every year, approximately 100 billion product information leaflets are printed worldwide. By implementing ePI across all AstraZeneca medicines, we could potentially save 500,000 trees, 50,000 tonnes of carbon dioxide equivalents (CO₂e), and 1.6 billion litres of water per year –equivalent to around 640 Olympic-sized swimming pools. Moreover, industry-wide adoption of ePI could reduce the environmental footprint of global medicine supply chains by an estimated 3.3 million tonnes CO₂e annually.¹²

Learnings from Japan, which has implemented a full transition to ePI, demonstrate how digital access can be embedded at scale. At the AstraZeneca Maihara manufacturing site, transitioning from paper leaflets to ePI saved 30 million sheets of paper in one year. In the European Union, Brazil and Egypt, AstraZeneca continues collaborating with health authorities to pilot ePI and co-develop practical pathways for effective and safe implementation.

50,000 tonnes

of CO₂e could be saved by transitioning to ePI across all of our medicines

500,000 trees

could be saved by transitioning to ePI across all of our medicines



Powering medicines manufacturing with renewable energy

AstraZeneca has set ambitious science-based targets to transition to net zero. We are working to design, develop and deliver medicines in the most environmentally sustainable way possible, using the latest science and innovation.

By 2025

We aim to:

- Have 100% renewable electricity consumption at sites worldwide and 100% electric road fleet where technically feasible
- Reduce total energy consumption from sites by 10% from 2015
- Double energy productivity at sites from 2015


By 2030

We aim to halve our value chain emissions*

By 2045

We aim to reduce absolute Scope 3 GHG emissions by 90% vs 2019 baseline to become science-based net zero

*2030 targets based on assumptions at time of target setting.





“We follow the science and are taking innovative climate action to decarbonise healthcare.”

Liz Chatwin

VP, Global Sustainability and Safety, Health & Environment, AstraZeneca

Following Climate Group’s RE100 criteria, we have developed internal standards and scoring mechanisms for energy sourcing proposals to improve utilisation and reduce emissions, focusing on:

- New renewable energy capacity (additionality)
- Energy purchase agreements that displace fossil energy sources close to where we consume that energy (geographic relevance) and
- Alignment between when our energy is generated and consumed (temporal relevance)

To date, through innovative industry-leading partnerships, 97% of all electricity used across AstraZeneca’s operations is from certified renewable sources.

Sweden

In 2024, our largest manufacturing site in Södertälje, Sweden delivered our Scope 1 and 2 target - to reduce emissions by 98% by 2026 from a 2015 baseline - 18 months ahead of schedule. This is significant as Södertälje accounts for 40% of our global production volume and is one of the largest pharmaceutical manufacturing sites in the world. Now, all of our locations in Sweden, including our strategic R&D centre in Gothenburg, have achieved this 98% Scope 1 and 2 emissions reduction target early.

We are also working with Statkraft to increase the supply of wind power in Sweden and will purchase 200 GWh

of renewable energy per year for 10 years. New wind farms will be commissioned, maximising the positive impact of our renewable energy procurement and focusing on sustainable innovation.

UK

In 2025, as part of our 15-year agreement with Future Biogas, we announced the launch of the UK’s first unsubsidised biomethane plant dedicated to the life sciences sector. Located in Lincolnshire, the plant will provide clean heat for all of AstraZeneca’s R&D and manufacturing in the UK. It will generate enough biomethane to heat the equivalent of over 8,000 homes a year, displacing approximately 18,000 tonnes of CO₂e emissions per year.

The new Moor Bioenergy plant will operate 24/7 and deliver additional renewable energy capacity to the UK network. The plant features innovative carbon capture technology which collects carbon dioxide produced during biomethane generation. Additionally, feedstock supplied to Moor Bioenergy for biomethane production will be from crops sourced close to the plant, with local farmers supported to drive sustainable farming practices. Multi-year contracts will offer farmers greater financial security, helping mitigate agricultural challenges related to fluctuating food crop prices and climate change.



Our progress is global

United States

We are collaborating with Vanguard Renewables to deliver renewable natural gas to power all our US R&D and manufacturing sites by the end of 2026, using biomethane from farm and food waste.

China

We are decarbonising our medicines manufacturing in China with clean heat, using biomethane and biomethane-based steam to supply our Wuxi manufacturing site.

Global supply network

As we continue to progress our Ambition Zero Carbon strategy, Södertälje, Sweden is our latest site to deliver a 98% reduction in Scope 1 and Scope 2 emissions (from 2015 baseline) measured against science-based targets.

We are also delivering sustainability at our R&D centres. For example, our state-of-the-art global R&D facility The Discovery Centre (DISC) in Cambridge, UK is a feat of environmental engineering and our commitment to sustainable science. The DISC is designed to the highest environmental standards to increase energy efficiency and work with the natural environment to reduce energy consumption through heating, cooling and lighting.

Our newest sites are designed and constructed to the highest environmental standards to deliver on our Ambition Zero Carbon Scope 1 and 2 targets from their first day of operation.





An award-winning Sustainability culture

Through our Green Labs programme, AstraZeneca is continually reducing the environmental impact of our lab operations and inspiring scientists across the organisation to adopt greener methods and practices.

From lab-based colleagues in R&D and Pharmaceutical Technology & Development to our operations leaders working on quality control in our manufacturing and supply network, colleagues across AstraZeneca are making our labs more sustainable. Today, more than 4,500 colleagues are optimising ways of working and delivering greener medicines. We are fostering a culture of sustainability and shifting mindsets to ensure we design, develop and deliver medicines in the most environmentally sustainable manner, while also gaining efficiencies.

In collaboration with My Green Lab, we are monitoring and tracking our sustainable performance within the lab space and identifying performance improvement opportunities. We have more than 129 lab spaces certified by My Green Lab in 19 countries, and 91 have achieved the highest level of certification of Green. In December 2024, we became the first organisation globally of any sector to achieve the new My Green Lab 2.0 certification and the first organisation to certify every operational site at Green level.

We are also taking action to reduce our energy consumption, engaging in the International Freezer Challenge and Switch Off Optimisation Program. Fostering healthy competition, our labs compete to save energy through activities such as freezer clean outs, maintenance, temperature set-backs and upgrades to more energy-efficient models.



The Discovery Centre (DISC), our state-of-the-art and sustainable global R&D facility in Cambridge, UK

In 2024, we avoided 7,962 kWh/ day, the equivalent of the energy used to charge an estimated 432,472 smartphones per day. We are adopting eco-friendly waste disposal methods and promoting the recycling of lab materials such as plastics and gloves which reduces our waste output. In addition, we are innovating our laboratory processes to reduce raw materials and solvent usage.

In the 2024 Freezer Challenge, My Green Lab and the International Institute for Sustainable Laboratories awarded AstraZeneca the Winning Streak Award for Biotech & Pharmaceuticals, for being at the top of our sector and surpassing our energy savings from the previous year.

A 24/7 carbon-free mindset

We regularly evaluate and enhance our approach to deliver the most positive impact for human and environmental health. 24/7 carbon-free electricity (CFE) is the latest step on our net zero journey, as we became a founding partner of the Climate Group's new 24/7 Carbon-Free Coalition in 2024.

24/7 carbon-free electricity means operating on 100% carbon-free electricity, 24 hours per day, 7 days a week by matching electricity demand with carbon-free generation, where and when consumption occurs.

Through the Coalition we aim to help enable a collective shift in corporate mindsets by demonstrating that 24/7 CFE is not only possible but beneficial to:

- Boosting competitiveness through more stable energy pricing
- Improving efficiency of energy use by accessing more accurate hourly information
- Future-proofing businesses through enhanced data capture on energy usage, and
- Reducing future costs by creating more market demand for renewables.

AstraZeneca prioritises additionality in our renewable energy strategy. At the same time, we realise that decarbonisation is not just about adding new renewables to the grid - it is also about improving their utilisation. Incorporating 24/7 CFE means using renewable energy from local sources that synchronise with local energy usage. This is an innovative and ambitious step to further our progress towards net zero.



Mitigating the risks of climate change to drive business resilience

As part of our **Ambition Zero Carbon** strategy, we're taking steps to future-proof our organisation and mitigate the risks presented by climate change. This is key to enable the continuous delivery of life-changing medicines to patients around the world.

As an organisation built on scientific innovation, managing risks is a core part of our business. When it comes to mitigating climate impacts and risks, we are investing now to ensure we can continue to lead a sustainable business and support patient needs. Mitigating physical climate risks is core to our operations, as challenges such as extreme temperatures and weather events could result in disruptions or delays to the manufacturing and distribution of medicines.

We are building resilience into our business by investing in at-risk sites and regularly reviewing supply chain design and inventory levels. For example:

- **In China**, we are protecting our new supply site in Qingdao from flooding by designing an elevated building. At our Wuxi site, we have invested in new drain capacity to manage flash flooding from extreme precipitation.

- **In France**, at our Dunkirk site, we have designed our new building to withstand high wind speeds and are collecting, storing and reusing rainwater to help protect the site from flooding.
- **In India**, we have learned from flooding experienced at one of our IT centres in Chennai. The site depends on city infrastructure that can be impacted by floods. Our local Business Continuity Plan supports the transfer of tasks to a backup site during any downtime caused by extreme weather conditions.

There are additional transitional and regulatory related climate risks in markets where we operate. Recognising this, we have integrated climate assessments into our enterprise risk management process, and our Ambition Zero Carbon strategy is delivered with oversight and input from risk and business continuity experts from across the organisation.





Expanding renewable power for healthcare in China

In 2024, the [Sustainable Markets Initiative \(SMI\) Health Systems Task Force](#) chaired by AstraZeneca CEO Pascal Soriot, [signed an industry-first renewable power agreement](#) to accelerate the transition to net-zero healthcare in China. In 2025, AstraZeneca, GSK and Takeda [announced an expansion](#) of this renewable power purchase agreement (PPA) to enable suppliers to unlock access to renewable electricity and support value chain decarbonisation.

The expansion of this innovative agreement enabled nine suppliers to collectively procure renewable power in China, provided through a mix of wind and solar energy. This collaboration will unlock approximately 225 GWh of renewable electricity annually for the research, development and manufacture of medicines, and our joint efforts across the pharmaceuticals sector since 2024 could result in annual emissions savings of 250,000 tonnes per year.

“Bold, scalable action is needed if we are to secure a liveable and sustainable future. Our work through the SMI in China to establish and then expand an industry-leading renewable power agreement sends a positive demand signal for green power and provides a blueprint for others to follow so that change can happen at an even greater pace.”

Pascal Soriot
CEO, AstraZeneca



CEO Pascal Soriot during London Climate Action Week

Contributing to the circular economy

In Texas, US, our Coppel manufacturing site is solely responsible for the production of a medicine used by millions of patients worldwide with high potassium levels. The process is unique, resulting in 155 to 200 million sachets made each year, which creates a projected average of 11,915 metric tons of landfill waste annually.

As part of our commitment to minimise pollution and eliminate waste in the development, manufacture and delivery of medicines, we designed a programme focused on circularity and landfill waste avoidance. We are following the science to ensure we can safely re-purpose the remaining filtered material from this manufacturing process for concrete companies to use in the construction industry.

13%

reduction in our total waste vs 2015

96%

of paper-based product packaging materials used in 2024 were from sustainable sources



Protecting and restoring nature

Climate change and nature loss are twin crises that are harming public and planetary health. Extreme temperatures and weather events, pollution and biodiversity loss are contributing to a rise in chronic and infectious diseases, increasing premature deaths, and undermining economic and social stability.

We are reducing our environmental impact, managing our dependencies on natural resources and protecting and restoring nature, in a way that follows the science.

- **Sustainable sourcing and resource use**
We promote efficient, circular use of resources like water, across our value chain and integrate sustainable sourcing to prevent land use change, deforestation and resource overexploitation.
- **Pollution minimisation**
We aim to eliminate waste in the development, manufacture and delivery of medicines, and lead our industry in managing pharmaceuticals in the environment (PIE).
- **Nature restoration**
We work collectively with stakeholders, including indigenous peoples and local communities (IPLCs), to protect and restore ecosystems through a focus on water stewardship and biodiversity.





AZ Forest

Through AZ Forest, our global reforestation and biodiversity programme, we aim to plant 200 million trees across six continents by 2030, restoring over 100,000 hectares of land. Co-designed with ecological experts and local communities, AZ Forest projects select diverse, locally appropriate tree species to maximise climate resilience and biodiversity benefits and reduce risks from pests and diseases. Local tree projects are monitored for an average of three years and large-scale reforestation projects for at least 10 years to ensure long-term survival. Local farmers, landowners and indigenous knowledge-holders are also involved in the projects to address socioeconomic needs and positively impact communities and livelihoods.

For example, in Ghana, AZ Forest is working with partners to enhance food availability and security by training farmers and communities to plant a mix of annual and perennial food and cash crops. The project has connected more than 1,900 local smallholder farmers from more than 23 communities to date. In addition, around 900 farmers were trained on bushfire management across 17 communities in 2024.

Horseshoe crabs

The development and manufacture of medicines requires extensive and rigorous pre-clinical and clinical testing to establish safety and efficacy. Medicines are manufactured under strictly controlled conditions with ongoing testing requirements to further ensure safety, quality and efficiency.

For injectable medicines, there are regulatory requirements to test raw materials, water systems and products during manufacturing for endotoxins which pose a high risk to patients if present in these medicines. Historically, horseshoe crab blood has been the only source of material to detect endotoxins. Horseshoe crabs are found in limited areas of the world and are listed as vulnerable by the International Union for Conservation of Nature (IUCN) given pressures from fishing, pollution, habitat loss, storms and increased

industrial use. On the East coast of the US, horseshoe crabs are also vital for the coastal food web, especially for migratory shorebirds. To reduce our dependency and disruption to this ecosystem, we are avoiding and reducing the amount of horseshoe crab blood we use from this area by switching to a synthetic alternative for testing where possible.

In 2024, we also launched a project to restore and regenerate US horseshoe crab populations through local action. Our partnership with the US National Fish and Wildlife Federation (NFWF) is restoring seven acres of climate-resilient beach habitat, monitoring horseshoe crab egg abundance for effectiveness and the Rufa Red Knot shorebird around Delaware Bay. This effort could help to sustain a stable horseshoe crab population for endotoxin testing, regional biodiversity and migratory shorebird feeding.

Barcelona wetlands

In Spain, we are working on a project to improve water quality and advance research in biopurification. In partnership with the Spanish National Research Council (CSIC), Catalan Water Agency, Consell Comarcal del Baix Llobregat, University of Barcelona and Collserola National Park with support from academia and local municipalities, we are funding the design and construction of a wetland to act as a nature-based water treatment system for effluent waters from the Rubí Wastewater Treatment Plant (WWTP).

Man-made wetlands can naturally purify water and improve the quality of discharge, promoting habitat recovery and biodiversity, as well as benefitting ecosystems. Using native plants for purification also has the potential to support local biodiversity. This initiative will monitor pollutant reductions compared to the traditional wastewater treatment plant, evaluating longer-term effectiveness and feasibility, and tracking improvements in biodiversity.



Improving health equity

We aim to close healthcare gaps to give people everywhere the chance to be as healthy as possible



Helping more people live their healthiest life

We aim to close healthcare gaps to give people everywhere the chance to be as healthy as possible. By 2030, we aim to positively impact 1 billion people, including 400 million people from underserved groups. In addition, we aim for AstraZeneca medicines to be available in more than 125 countries.

Everyone deserves the opportunity to live their healthiest life, yet quality and timely healthcare remains out of reach for too many people across low, middle and high-income countries.

Factors such as gender, geography, income level and the environment can affect the care individuals receive, and many people face barriers to screening, early detection of disease, precision diagnosis and treatment. By closing these care gaps, we can improve equitable health outcomes. We're taking action to improve health equity in:

- **Science**
We are ensuring our genomics research and clinical trials are representative of the populations most impacted by disease, and we are enabling researchers to re-use our science to advance open innovation.
- **Healthcare delivery**
We are closing care gaps throughout the patient journey by improving health education, advocating for policy change, and partnering to bring evidence-based solutions tailored towards those at risk. Our focus is across the therapy areas we work in, including lung health, cardiovascular, renal, metabolic and rare diseases.
- **Community investment**
We are addressing the root causes of health inequities worldwide by helping to prevent disease, promote health and science education, and support urgent health needs in underserved communities, through partnerships with non-profit organisations.




Ensuring our science represents those most impacted by disease

With a truly global footprint and one of the broadest portfolios in our sector, we're embedding health equity in everything we do, including in our science. We're focusing on enhancing genomics and clinical trial representation to develop more effective medicines, for more patients.

Genomics

We are transforming how we discover and develop new medicines by ensuring our genomics data represents patients impacted by disease, including those from under-studied global communities such as people of Latino, Asian, African and Middle Eastern descent. This enables us to better understand disease biology, discover new biomarkers, identify new targets and match the right patient to the right medicine. To do that, we are collecting data from our clinical trials and partnering with over 60 academic, industry, government and not-for-profit organisations across 19 countries.

One example is our active membership in a consortium that launched the Discover Me South Africa study. This study recruited 100,000 people to integrate health and genetic data in Durban, South Africa, in partnership with the University of KwaZulu-Natal, Inkosi Albert Luthuli Central Hospital and the KwaZulu-Natal Department of Health, as well as other leading industry partners. Over two years, this collaboration aims to expand the scale of genomic data and analysis to provide diverse, large-scale, real-





world data that will help us better understand disease-risk prediction and inform drug discovery. This joint effort aims to create a roadmap to help guide personalised care in South Africa and across the region.

Clinical trials

We are ensuring our clinical trials are representative of the people most impacted by diseases that our medicines treat. This is critical to improving access to innovative therapies and ensuring our medicines are effective in different populations. To do that, we're expanding to new clinical trial sites and working with community health organisations to raise awareness, build trust and increase clinical trial enrolment among underserved communities. We're also investing in strengthened principal investigator expertise and collaborating with industry groups and regulatory agencies to create best practices in enhancing clinical trial representation.


In 2024, we:

- Implemented clinical trial simulations to identify and address potential barriers, help reduce the burden of participation and improve protocol adherence.
- Advanced collaborations including with InVision to bring to market novel AI software as a medical device to improve diagnosis of rare diseases (such as cardiac amyloidosis).
- Delivered a Phase III trial, one of the first pivotal studies for asthma which employed approaches including 100% virtual clinic visits and home delivery of study medication to reduce the patient burden, whilst demonstrating strong efficacy in treating asthma.

Data from 1.4 million people enabled:

16 new target selections

50 pipeline decisions



Enabling discovery through Open Innovation

Through our Open Innovation programme, we enable the re-use of our science, tools, technologies and expertise with external partners, supporting the broader scientific community to advance research to improve health outcomes.

Projects using our molecules have received more than US\$100 million in funding from grant agencies since 2014, resulting in scientific advances that have been showcased in over 100 journal publications. Over the past decade, we have supported scientific discovery in more than 20 disease areas, including many beyond AstraZeneca's core focus. We've also engaged in over 1,000 collaborations across 40 countries. We currently have two ongoing clinical trials, more than 100 preclinical studies and collaborative research projects and more than 20 public-private partnership projects aimed at addressing key scientific challenges under this programme.



Improving lung health equity

We're collaborating with governments, health systems and communities to close healthcare gaps along the entire patient journey, from prevention and screening to early detection, precision diagnosis and treatment.

Lung diseases such as lung cancer, COPD and asthma profoundly impact the health of millions of people, economies and the planet. Multiple determinants of health, including poverty, smoking, air pollution and proximity to healthcare services, contribute to poor lung health outcomes and may act as barriers to detection, diagnosis and guideline-based care.

AstraZeneca is partnering with stakeholders to close care gaps in lung screening, early detection, diagnosis and treatment. We are:


- Leveraging data analytics to understand common factors that compound to worsen lung health inequities
- Collaborating with local health systems to target interventions towards underserved patients
- Advocating for policy changes to support comprehensive lung disease management

\$4.3 trillion

the estimated global burden of COPD by 2050, a leading cause of hospital admissions and the world's third leading cause of death¹³

>50%

of lung cancer cases are diagnosed at late stages, despite detection at early stages significantly improving survival outcomes





Our progress is global



United States

In the US, we use data on socioeconomic status, air quality, lifestyle habits and insurance coverage to provide targeted care for those populations at risk of lung diseases like COPD and lung cancer. Our partnership with the Association of Community Cancer Centers uses data and mapping tools to pinpoint areas down to the postal code level where groups are at highest risk.



United Kingdom

Up to 59% of patients attending lung cancer screening programmes globally have evidence of COPD and many are missing opportunities for earlier diagnosis, treatment and participation in clinical research. We are collaborating with health services in the UK to identify more patients with COPD and increase enrolment in our clinical trials.

As a result, 33% (17 of 51) of those randomised for a trial in the UK were identified directly from targeted lung health checks – triple the average site randomisation rate for the study compared to other sources such as referral from primary care. Based on this successful pilot, we are scaling the initiative more broadly in the UK and expanding to the US and Canada.

“Our ambition is to transform lung outcomes globally. We’re using data and insights to understand healthcare barriers along the patient journey and address disparities at the postal code level. This informs how we work in partnership to deliver targeted interventions for those at greatest risk of lung diseases.”

Dave Fredrickson

EVP, Oncology Haematology Business Unit, AstraZeneca

The Lung Ambition Alliance (LAA) is a flagship global programme we are proud to partner on. This global coalition has the mission of eliminating lung cancer as a cause of death by improving earlier detection, precision diagnosis, treatment and quality of care. LAA is now active in 50 countries.

Through this initiative and our commitment to leveraging technology to advance lung cancer care in low-and-middle income countries, we also collaborate with Qure.ai to screen patients with AI-enabled X-rays. This is an effective and cost-efficient solution for screening, and we aim to screen 5 million patients by the end of 2025.

Additionally, through the Lung Cancer Policy Network, we are collaborating with leading experts to publish policy recommendations, cost-effectiveness analysis, and implementation frameworks to improve lung cancer care around the world.

As members of the International Respiratory Coalition (IRC), we are focused on transforming respiratory care and reducing deaths from respiratory diseases by one-third globally by 2030 – in line with the [UN Sustainable Development Goals](#). The IRC and its national members empower national respiratory coalitions to work with governments and health stakeholders by advocating for the prioritisation of respiratory health as a key public health concern in national health policies. To support this goal, the IRC urges governments and policy makers to establish funded respiratory strategies.

These collaborations are helping to improve patient outcomes and reduce the burden of lung diseases on the health system.



Addressing heart and kidney health in vulnerable communities

Hundreds of millions of people live with cardiovascular, renal and metabolic diseases, including hypertension, diabetes and CKD. These silent killers disproportionately impact vulnerable communities.

“Heart and kidney health are often interconnected. With earlier diagnosis, intervention and treatment of cardiorenal diseases, we have a tremendous opportunity to prevent life-threatening complications, and reduce the economic and environmental impact of disease across the continent.”

Ruud Dobber
EVP and President, BioPharmaceuticals Business Unit
AstraZeneca

A decade of impact through Healthy Heart Africa

Healthy Heart Africa (HHA) launched in 2014 to address the growing burden of cardiovascular diseases in Africa. By 2024, the programme had reached 12.9 million people with elevated blood pressure, surpassing its original goal of reaching 10 million people by 2025.

From its inception, HHA has engaged governments to shape healthcare ecosystems, focusing on informing policy, including national NCD guidelines, training healthcare workers, establishing training guidelines and increasing public awareness through integrated primary healthcare screening.

With its success in improving health outcomes and strengthening local health systems, HHA expanded its scope in 2024 to include CKD. With an estimated 15% of people in Africa affected – exceeding the global average – CKD often goes undetected and undertreated due to limited public awareness and health policies. The expansion of HHA will help to improve prevention and screening services to detect and treat CKD earlier.



Improving health equity for rare disease patients through genomic screening

Living with a rare disease is inherently inequitable. We are dedicated to improving the lives of those living with rare diseases, and the people who support them. In our rare disease business unit Alexion, as part of our ambition for 2030, we are aiming to reach six times as many patients than we did 2022 across 100 countries with our transformative rare disease medicines. We are on track to reach this commitment – in 2024, our medicines were available in more than 70 countries.

One way we're delivering for rare disease patients is through our founding membership of the Rady Children's Institute for Genomic Medicine (RCIGM)'s BeginNGS Consortium. Alexion provides strategic leadership and technical expertise as RCGIM works to advance and evaluate the scalability of BeginNGS (pronounced “beginnings”), a diagnostic and precision medicine guidance tool to screen newborns for approximately 400 genetic diseases that have known treatment options using rapid Whole Genome Sequencing (rWGS).

The Consortium includes established leaders in the genomics and biotech space, including representation from pharmaceutical and biotech companies, several rare disease patient groups, and high-profile academic partners, who will collectively provide strategic and technical expertise. Two clinical studies published in December 2024 show the potential for genomic screening in newborns to address high rates of infant hospitalisation and mortality in the United States, and beyond.



Empowering global young health leaders

For 15 years, the Young Health Programme (YHP) has been empowering young people to make more informed choices about their health and catalysing a global, youth-led advocacy movement.

With a focus on disease prevention, the YHP empowers young individuals aged 10–24 from underserved communities with the knowledge and tools to make healthier choices, thereby mitigating long-term health risks, shifting from reactive ‘sick care’ to a proactive approach focusing on prevention and reducing the environmental footprint of care.

CEO Alexion Marc Dunoyer at the One Young World Regional Congress
Costa Rica, 2025





“We are taught how to have conversations in policy spaces, so it’s not just a chance to give me a voice, but you’re giving me a technique so that my voice is heard”

Mamkhabela

YHP/UNICEF Youth Advocate and Student from South Africa

Delivered in partnership with over 60 non-profit organisations, including UNICEF and Plan International, and informed by research from the Johns Hopkins Bloomberg School of Public Health, the YHP operates in more than 40 countries as a flagship health equity programme. From Brazil to Spain, Egypt and Kenya, the programme has directly reached over 19.5 million young people, provided training to more than 900,000 people, and has positively shaped 18 policies and laws since its launch in 2010. To date, 20,000 employees have volunteered more than 99,000 hours through the programme.

Aligned to the United Nation’s Sustainable Development Goal 3.4, the YHP aims to prevent the most common NCDs such as cancer, diabetes, heart disease, and respiratory disease, by addressing the primary risk factors for NCDs, such as tobacco use, harmful use of alcohol, physical inactivity, unhealthy diet, and exposure to air pollution. Some of these behaviours can be largely down to personal choices, but these and other factors are also heavily affected by social and environmental influences, and by policy.

For example, in South Africa, 1 in 5 children may face future health risks from food related illnesses. Through our partnership, UNICEF South Africa works with youth advocates to support the government to improve the food environment for all young people. As we celebrate the 15th anniversary of the YHP and anticipate the UN Fourth High-Level Meeting on NCDs in 2025, we have a pivotal opportunity to mobilise investment for more resilient health systems and deliver accountability for young people, society and our planet.

Mamkhabela, a YHP/UNICEF youth advocate and student from South Africa

Supporting community recovery and resilience in disaster affected areas

Providing support for disaster relief and humanitarian work is an important part of our contribution to society. Through partnerships with trusted non-profit organisations, we enable support through the provision of financial donations, product donations, and other solutions to allow greater access to care. We are committed to working with health systems stakeholders to enable the supply of medicine to patients and support the resilience and recovery of healthcare facilities in communities with the greatest unmet need.

We recognise that the right to adequate healthcare is linked to rights to clean water, sanitation, food and shelter, and therefore take a holistic approach to improve access to integrated, quality, essential healthcare that is safe, effective and patient-centred.

In September 2023, a major earthquake struck Morocco, devastating communities and causing widespread destruction, particularly in remote and difficult-to-access areas. Many families lost everything – seeking temporary shelter and facing urgent needs for clean water, medical care, and education. Schools, health facilities, and other vital infrastructure were heavily damaged, disrupting essential services for thousands of families.

In response, we provided humanitarian support to two longstanding partners, the British Red Cross and Project HOPE, alongside employee matched funding. The donation has helped to reach more than 80,000 people with humanitarian assistance. Ten sanitation facilities were built, and more than 1,000 families have been helped to rebuild their homes, with over 2,300 more provided with appropriate shelter units that are suitable to live in medium-term.

With the significant toll on the mental health of those who have been impacted, our funding also enabled workshops and services to support their needs, as well providing cash grants and vocational training programs to help kickstart their livelihoods. Together with our partners, we are continuing to support communities impacted by disasters and humanitarian emergencies around the world, with a focus on providing immediate relief and long-term recovery.



© Benoit Carpentier, IFRC

Improving student health with sustainable access to clean water

Recognising the critical importance of water as a vital resource for healthy lives and climate resilience, AstraZeneca's Global Innovation Technology Centre in Guadalajara, Mexico launched a Rain Schools programme in the local community. We partnered with Isla Urbana, a non-profit organisation, to install rainwater harvesting systems in 40 schools in Guadalajara and Zapopan, with the primary objective of ensuring a reliable and clean water supply for sanitation facilities. This is expected to benefit over 10,000 students attending the schools and capturing at least 100,000 litres for use in the school facilities each year.

The programme also involves working in collaboration with parents, teachers, principals and students to foster community engagement and strengthen water conservation practices by promoting rainwater harvesting as a sustainable and more reliable alternative to municipal supply.

This initiative directly addresses critical health and sanitation challenges in elementary schools while championing environmental sustainability and integrating environmental education from an early age. The programme includes technical training for school communities to ensure the proper use and maintenance of rainwater harvesting systems, as well as practical workshops to raise awareness about the importance of responsible use of water resources and handwashing to prevent disease.



Improving access to healthcare

We are one of the leading pharmaceutical companies in emerging markets, which underscores our commitment to ensuring access to innovation in low- and middle-income countries.

We're improving access to healthcare and medicines through patient assistance, early access programmes and tiered pricing strategies.

“At AstraZeneca, we are embedding health equity into everything we do. We aim to understand how health determinants affect outcomes across communities, from high to low and middle-income countries, and take action to address these disparities. Our focus includes major diseases like cancer, chronic respiratory and cardiovascular conditions, and rare diseases.”

Iskra Reic
EVP, International, AstraZeneca



Recognition for our efforts to increase equitable access to healthcare

AstraZeneca was ranked in the top five companies in the Access to Medicine Index (ATMI) in 2024, reflecting our ambition to increase equitable and affordable patient access to life-changing treatments and strengthen health systems resilience.

ATMI is an independent ranking of 20 of the world's largest pharmaceutical companies and evaluates their efforts to improve access to medicine in low and middle-income countries. It focuses on three technical areas: Governance of Access; Research and Development (R&D); and Product Delivery.

AstraZeneca ranked fourth in both Governance of Access and Product Delivery, where ATMI recognised a best practice in reporting outcomes for our access strategies across different countries' income classifications. We also performed well in R&D, with ATMI highlighting our access planning process particularly in emerging markets, and the largest pipeline for NCDs of companies in scope.



Strengthening health systems resilience

We aim to contribute to stronger health systems
that can meet health needs, today and tomorrow



Building health systems for today and tomorrow

By 2030, we aim to strengthen health systems in 45 countries through partnerships with governments and evidence-based advocacy.

Health systems must be able to meet people's health needs today, while also preparing for the challenges that will continue to strain them in the future, including the growing burden of disease, ageing populations and environmental crises. Currently, millions are without timely, effective and integrated diagnosis and treatment and health systems are unable to plan for future shocks and crises.

To build resilient and sustainable health systems, AstraZeneca partners with health systems stakeholders to transform care by providing evidence-based recommendations and co-creating solutions that help to slow down disease progression, reduce hospital admissions, and prevent premature deaths globally. We do this through:

- **Policy change**

We advocate for evidence-based policy change at the health system level through impactful public-private partnerships that harness cross-sectoral expertise and resources at global and local levels.

- **Practice change**

We partner with healthcare providers locally and leverage innovative technologies to act earlier to prevent, detect and diagnose disease, enabling patients to access guideline-based care.

This not only saves lives, but also reduces healthcare budgets, resources and the impact of healthcare delivery on the planet.



Improving patient outcomes and reducing disease progression

Over three billion people are living with chronic diseases, with someone dying prematurely every two seconds. This puts an enormous burden on societies: the five most common NCDs are projected to cost the global economy \$47 trillion by 2030.¹⁴

With record-high waiting lists, workforce shortages and overburdened emergency services, investment in and partnership to prevent, detect and treat diseases early is critical to save lives, reduce healthcare costs and mitigate the impact of the delivery of care on the planet.

Through our Accelerate Change Together – or ‘ACT On’ – programmes, we are partnering with stakeholders, including governments, healthcare providers and patients to transform chronic disease management in COPD, CKD, heart failure and amyloidosis. These programmes focus on raising disease awareness, advocating for policy change, and collaborating with health systems to optimise treatment pathways.

Our ‘ACT on’ ambitions:

Amyloidosis

Halve the time to diagnosis by 2028 and double the diagnosis rates specifically of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM), a type of amyloidosis that often leads to heart failure (HF), by 2030.

CKD


Reduce the proportion of patients progressing to kidney failure by 20% by 2025.

COPD

Cut the COPD exacerbation rate in half by 2030 and reduce the associated cardiopulmonary mortality risk.

Heart Failure

Improve the lives of heart failure patients and halve heart failure hospitalisation and mortality rates by 2030.





Strengthening health systems through public-private partnerships

Through the Partnership for Health System Sustainability and Resilience (PHSSR), a non-profit, multisector, global collaboration active in more than 30 countries that AstraZeneca co-founded in 2020, we are working with partners toward a common goal of building more sustainable and resilient health systems.

“Healthy societies and economies are powered by healthy populations. The private sector is a critical partner for governments to ensure that the world can deliver a sustainable and resilient future.”

Sjoerd Hubben
SVP, Global Corporate Affairs, AstraZeneca

To date, PHSSR has commissioned more than 30 research reports, providing independent, evidence-based recommendations to strengthen health systems and facilitate cross-border best practice sharing, working with national experts with firsthand experience.

In Egypt, our collaboration with the Ministry of Health through the PHSSR has fostered a multi-stakeholder dialogue that includes payers, buyers and regulators. It has resulted in commitments to support sustainable financing, digital transformation and systematic data generation. This includes AstraZeneca’s support of a Healthtech Innovation Hub to accelerate digitalisation and data generation across Egypt’s healthcare system. PHSSR recommendations are also strengthening our support across several Presidential initiatives in Egypt, particularly in lung and liver health, where we have screened 130,000 lung cancer patients and trained over 1,500 healthcare workers.

Through the PHSSR we are also supporting the Egypt Ministry of Health’s sponsorship of World Health Assembly resolutions on Rare Diseases and Lung Health, to enhance national dialogue for sustainable financing and reinforce the Egyptian government’s aspiration for leadership in healthcare innovation. We are also working closely with Egypt’s healthcare accreditation and regulatory body’s “green facility” accreditors to support the implementation of green healthcare practices and the training of over 450 professionals to manage green hospitals, with a goal to accredit 25 green healthcare facilities.

In Abu Dhabi, recommendations on the strategic use of AI in healthcare and the need to prioritise early action through the PHSSR have served as an anchor for further collaboration with the Department of Health. There is now greater focus on the development of a Breast Cancer AI Quality Improvement Tool, as well as recommendations to decarbonise the CKD patient pathway. The global PHSSR Summit also took place in Abu Dhabi in 2024, co-hosted by the Abu Dhabi Department of Health. Together with Ministers from Greece and Egypt, this Summit was a forum for the UAE to exchange best practices on addressing pressing challenges for health systems, specifically on acting earlier on NCDs, sustainable financing and the interconnection between climate and health.

In Belgium, since the PHSSR country report launch in 2023, two key milestones have been achieved. Firstly, the partnership convened a group of key national healthcare stakeholders which is now meeting regularly to develop policy solutions to accelerate building a future-proof, value-based healthcare system in Belgium. Secondly, Belgian and EU-level stakeholders have convened in the European Parliament on the topic of ‘sustainable health for sustainable growth’. This enabled dialogue on solutions to improve resilience and sustainability of health systems – including early action on NCDs, a key priority for the European Union.



Chair Michel Demaré met with key stakeholders at the PHSSR Summit in Abu Dhabi, 2024



Educating the next generation to deliver sustainable healthcare

Training 10,000 future doctors on climate impact on health and sustainable healthcare.

AstraZeneca played a central role in establishing a trailblazing network to train more than 10,000 medical students across Europe with skills to address the interconnection of climate and health. This was achieved through a collaboration between members of the SMI Health Systems Task Force, chaired by CEO Pascal Soriot, and leading universities, with support from the World Health Organization.


The European Network on Climate & Health Education (ENCHE), launched with leading medical schools from Belgium, France, Germany, Ireland, Italy, Poland, Portugal, Slovenia, Sweden, Spain, Switzerland and the UK, will integrate climate and health teaching into curricula to help medical students recognise, prevent and treat the increasing burden of the climate crisis on public health, as well as deliver sustainable healthcare solutions.

Currently, medical education does not consistently provide instruction on the interconnection between climate and health, with training often relying on the knowledge of individual faculty members and the engagement of student groups. The ambition of

the Network is to provide best-in-class knowledge and skills training across undergraduate degree programmes to address current and future climate-related health threats.

ENCHE by the University of Glasgow and is a regional hub of the Global Consortium on Climate and Health Education (GCCHE) at Columbia University Mailman School of Public Health. The GCCHE will offer expertise and advice to the Network, as well as promote transatlantic collaboration on climate and health education. The Network launched in October 2024 and has now grown to a membership of more than 38 medical schools.

AstraZeneca's contribution to the SMI and initiatives like ENCHE underline our commitment to mobilise and partner with our peers across the healthcare sector and beyond to accelerate scalable action and contribute to a healthier future.





How we do business

Guided by our Values, we invest in our people to create long-term value, resilience and trust by operating responsibly, ethically and with robust governance



Our Values

Our work is guided by our Values which shape our decisions, behaviours and culture. Driven by these principles and the potential of science, we focus on accelerating the delivery of life-changing medicines, creating lasting value for patients, society and shareholders.

Our Values

- **We follow the science**
Pushing the boundaries of science and working creatively with partners and collaborators.
- **We put patients first**
Striving to understand patients' needs and considering them in every decision we take.
- **We play to win**
Building high-performing, inclusive and diverse teams and making the right choices to win.
- **We do the right thing**
Employing high ethical standards when carrying out all aspects of our business globally.
- **We are entrepreneurial**
Acting with urgency, bravery, resilience and taking smart risks.





Our people

Everything we do is underpinned by being a great place to work.

Being purposeful about people, we aim to deliver great employee experiences by being champions of inclusion and diversity and fostering personal growth and enterprise leadership.

- **We foster personal growth and enterprise leadership**

We are committed to advancing a culture of lifelong learning across our company so that every employee can continuously develop their skills, capabilities and behaviours, and adapt to future needs. By creating everyday development experiences, we provide limitless opportunities for employees to exercise their natural curiosity, empowering us all to develop new ideas and thrive in a fast-changing world.

- **We cultivate an inclusive environment where individuals can authentically express themselves**

We believe that inclusion is a right and diversity is a strength. Both make a fundamental contribution to the success of our Company because innovation requires breakthrough ideas that only come from a diverse workforce empowered to challenge conventional thinking.

- **We enable an agile organisation through intuitive tools, technology and optimised ways of working**

We are harnessing the potential of technology, simplifying how we work and scaling our business for the future.



Our governance and ethics

By embedding ethical behaviour and transparent policies throughout our company activities and value chain, we strive to deliver positive impact that builds on the direct benefits of our life-changing medicines.

- **We seek to build long-term resilience and trust**
We consistently uphold integrity, transparency and fair treatment across our organisation and value chain. This enables us to innovate and operate effectively, supporting our purpose to push the boundaries of science to deliver life-changing medicines.
- **We ensure robust governance**
We adhere to legislation, regulations, policies and standards to ensure ethical and transparent conduct across our business activities and value chain.
- **We maintain high standards and accountability**
We enforce high standards of conduct and accountability in all areas across our business and value chain, which supports partners and builds capabilities.





The road to 2030

Progress on our ambitions is driven by our people



The road to 2030

Sustainability is a shared responsibility.

We encourage all employees to consider Sustainability in their role and their teams.



Gary Lu

Senior Director, Safety, Health & Environment, Asia Pacific, AstraZeneca

The healthcare sector has a significant environmental footprint and there is a pressing need for more sustainable practices. Expanding access to renewable power is crucial in regions like China, where rapid industrial growth presents both a challenge and an opportunity to implement eco-friendly practices, ensuring a sustainable future and aligning with national and global net-zero goals.

For the past two years, I have supported China renewable power purchase projects under the Sustainable Market Initiative. By collaborating with internal teams and external partners to source as a group, we've helped advance projects that enable our own operations and suppliers to access renewable power in China with more robust screening of the renewable energy providers and reduced risks, better quality renewables and a lower price. This is not just a corporate responsibility but a personal passion, as I see the potential for these initiatives to create lasting, positive environmental impacts.



Kohei Nishiyama

Associate Director, Genetic and Metabolic Disorders, Alexion Japan

In hypophosphatasia (HPP), an inherited metabolic bone disease, diagnostic lag is a major issue as there is low awareness among HCPs and there are a variety of clinical symptoms. We are working with local governments and dental societies to add a check for premature exfoliation of primary teeth to the public dental check-up, which 99% of infants in Japan undergo, as it is a specific symptom that highly suggests the possibility of HPP. This initiative is currently being implemented in municipalities covering 30% of the infant population.

The efforts of a single company alone are not enough to sustainably provide patients with rare diseases with fair diagnostic and treatment opportunities. Our team's passion to support patients has helped motivate external stakeholders, and together we are making progress for rare disease patients.



Leonardo Bueno Estevez

Senior Director, Regional Supply - Americas, AstraZeneca

Nina Shah

Global Head of Multiple Myeloma Clinical Development and Strategy, AstraZeneca

AstraZeneca's commitment to sustainability is reflected in our two San Francisco Bay Area sites: a research and development centre in South San Francisco and a manufacturing facility in Redwood City. Both locations are focused on creating a legacy of responsible manufacturing and R&D practices.

Our South San Francisco site has earned the prestigious LEED Platinum certification and was the first to achieve a My Green Lab Green rating. In Redwood City, we have significantly reduced our water consumption and waste generation, alongside decarbonisation efforts. By encouraging our team to innovate ways to reuse and recycle, we contribute to a more sustainable and resilient organisation. Every small step we take to reduce our environmental footprint can lead to significant, transformative changes, ensuring a healthier planet for future generations.



Danilo Guidini Lopes

**Associate Medical Director, Oncology and Haematology,
AstraZeneca Brazil**

In my role I am dedicated to making an impact across various tumor types in Oncology, with a particular focus on advancing lung cancer and lung health initiatives. By leading innovative projects aimed at early diagnosis and enhanced treatment pathways, we are improving patient outcomes and simultaneously alleviating the long-term pressure on healthcare systems.

This approach allows us to implement precision in care, reducing the necessity for more intensive, resource-heavy interventions in the future. And with these comprehensive lung health strategies, we are supporting more resilient and sustainable healthcare systems capable of meeting the demands of an ever-evolving landscape.



Claudio Longo

Country President, AstraZeneca Italy

We are actively collaborating with stakeholders across the Italian healthcare ecosystem to drive policy changes that support a more sustainable and resilient health system.

As part of this commitment, we have recently launched the Alliance for Health Equity in Italy – an innovative multi-sector initiative that brings together leaders from business, government, patient organisations and NGOs. Together, we are working to identify and address the root causes of healthcare disparities, with the shared goal of improving equitable access to care for all.



Alex Alderton

**Senior Director, BioPharmaceuticals R&D,
AstraZeneca UK**

There is a strong connection between a healthy planet and healthy people. That's why it's so important we embed sustainability across every aspect of our science.

Through technology we developed with our partners, we are using acoustic tube technology to seamlessly transfer nanolitre-size quantities – one billionth of a litre – eliminating contamination and increasing the speed, sustainability and efficiency of molecule screening. This is one of the exciting areas of sustainable science we're leading at our state-of-the-art global R&D facility, The Discovery Centre (DISC) in Cambridge, UK.



Suzan Shuman

GCC Business Unit Director - CVRM, AstraZeneca UAE

Partnerships have the power to reshape how care is delivered. One example I'm proud of is our partnership with SEHA, Abu Dhabi's public health provider, to reimagine kidney care. Inspired by COP28 and aligned with the UAE's Net Zero 2050 Strategy, we advocated for earlier screening policy and other interventions as a strategic step toward better patient outcomes, less carbon emissions and more resilient health systems.

This work matters deeply to me because it proves that sustainability and better health outcomes can go hand in hand. When care pathways serve both people and the planet, we create a future where patients never have to choose between quality of care and quality of life.



References

1

World. Environmental health [Internet]. Who.int. World Health Organization: WHO; 2020 [cited 2025 May 26]. Available from: https://www.who.int/health-topics/environmental-health/estimating-the-morbidity-from-air-pollution-and-its-economic-costs#tab=tab_2

2

Health Care Without Harm. Health care's climate footprint how the health sector contributes to the global climate crisis and opportunities for action. Health Care Without Harm Climate-smart health care series Green Paper Number One Produced in collaboration with Arup [Internet]. 2019. Available from: https://global.noharm.org/sites/default/files/documents-files/5961/HealthCaresClimateFootprint_092319.pdf

3

Behinaein P, Hutchings H, Knapp T, Okereke IC. The growing impact of air quality on lung-related illness: a narrative review. Journal of Thoracic Disease [Internet]. 2023 Sep 28;15(9). Available from: <https://jtd.amegroups.org/article/view/77740/html>

4

Jiang XQ. Air Pollution and Chronic Airway diseases: What Should People Know and do? Journal of Thoracic Disease. 2016 Jan;8(1):E31-40.

5

World Health Organization. Air Pollution [Internet]. World Health Organization. World Health Organization; 2024. Available from: https://www.who.int/health-topics/air-pollution#tab=tab_1

6

Trixeo Aerosphere approved in the UK as first inhaled respiratory medicine using next-generation propellant with near-zero Global Warming Potential [Internet]. Astrazeneca.com. 2025. Available from: <https://www.astrazeneca.com/media-centre/press-releases/2025/trixeo-aerosphere-approved-in-the-uk-as-first-inhaled-respiratory-medicine-using-next-generation-propellant-with-near-zero-global-warming-potential.html>

7

Prioritizing health: A prescription for prosperity | McKinsey [Internet]. www.mckinsey.com. Available from: <https://www.mckinsey.com/industries/healthcare/our-insights/prioritizing-health-a-prescription-for-prosperity#section-header-1>

8

Remes J, Wilson M, Ramdorai A. How investing in health has a significant economic payoff for developing economies [Internet]. Brookings. 2020. Available from: <https://www.brookings.edu/articles/how-investing-in-health-has-a-significant-economic-payoff-for-developing-economies/>

9

World Health Organisation. Noncommunicable Diseases [Internet]. World Health Organization. 2024. Available from: <https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases>

10

NCD Alliance. Financing NCDs [Internet]. NCD Alliance. 2015. Available from: <https://ncdalliance.org/why-ncds/financing-ncds>

11

Early intervention key to driving sustainability in cardiorenal care [Internet]. Astrazeneca.com. 2024 [cited 2025 May 26]. Available from: <https://www.astrazeneca.com/media-centre/articles/2024/early-intervention-key-to-driving-sustainability-in-cardiorenal-care.html>

12

Electronic Product Information (ePI) – digitalising medicine information for patients [Internet]. Astrazeneca.com. 2024. Available from: <https://www.astrazeneca.com/media-centre/articles/2024/electronic-product-information-epi-digitalising-medicine-information-for-patients.html>

13

Chen S, Kuhn M, Klaus Prettnner, Yu F, Yang T, Till Bärnighausen, et al. The global economic burden of chronic obstructive pulmonary disease for 204 countries and territories in 2020–50: a health-augmented macroeconomic modelling study. The Lancet Global Health [Internet]. 2023 Aug 1;11(8):e1183–93. Available from: [https://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X\(23\)00217-6.pdf](https://www.thelancet.com/pdfs/journals/langlo/PIIS2214-109X(23)00217-6.pdf)

14

The Investment Case for Transforming Health Care to Act Early on Non-Communicable Diseases - FP Analytics [Internet]. fpanalytics.foreignpolicy.com. Available from: <https://fpanalytics.foreignpolicy.com/2023/01/05/the-investment-case-for-transforming-health-care-to-act-early-on-non-communicable-diseases/>



For the health of people, society and the planet